Cell Therapy – What Does It Take To Become A Mainstream Option?

While cell therapies are still a small segment of therapeutics, the landscape is rapidly changing — with over 1000 ongoing clinical trials and several recent commercial approvals. Scalable biomanufacturing for cell therapies is crucial to making these therapeutic products successful and accessible to more patients. But gaps in capacity and technologies are holding these therapies back from wide adoption.

In this Q&A, Eytan Abraham, Ph.D., VP and Business Head of Cell Therapy, Gene Therapy and Nucleic Acid Franchises, and Bruce Thompson, Ph.D., VP and Technical Head of Cell Therapy Franchise, Resilience, discuss the main biomanufacturing bottlenecks and how to overcome them.